CytomX Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 11, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 11, 2024
CTMX$1.98-9.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Operations and Comprehensive Loss
| Year Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Revenues | $101,214 | $53,163 |
| Operating expenses: | ||
| Research and development | 77,680 | 111,649 |
| General and administrative | 30,018 | 42,849 |
| Total operating expenses | 107,698 | 154,498 |
| Loss from operations | (6,484) | (101,335) |
| Interest income | 9,837 | 1,678 |
| Other income (expense), net | (30) | 340 |
| Income (Loss) before income taxes | 3,323 | (99,317) |
| Provision for income taxes | 3,892 | — |
| Net loss | (569) | (99,317) |
| Other comprehensive loss: | ||
| Unrealized gain on available-for-sale investments, net of tax | 85 | 252 |
| Total comprehensive loss | $(484) | $(99,065) |
| Net loss per share, basic and diluted | $(0.01) | $(1.51) |
| Shares used to compute net loss per share, basic and diluted | 73,808,237 | 65,739,844 |
CYTOMX THERAPEUTIC, INC.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.